

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-02-27 to 2026-03-29 (30 days)

Generated: 2026-03-29 09:00:09

Executive Summary

Executive Summary: Illumina (ILMN) Sentiment Analysis (Feb 27 - Mar 29, 2026)

Sentiment analysis for Illumina (ILMN) from February 27 to March 29, 2026, indicates a predominantly neutral market perception with a slight negative bias. Out of 91 analyzed items, 48% were classified as neutral, 30% as negative, and 22% as positive. Key drivers for positive sentiment included strong individual stock performance amidst a broader market downturn and strategic business collaborations. Conversely, negative sentiment was primarily influenced by bearish stock price forecasts and a notable volume of highly negative scientific research publications.

The most significant positive event was Illumina's stock outperforming competitors, recording a 2.96% gain on a generally poor trading day and extending a five-day winning streak. Further positive momentum stemmed from the expanded precision oncology testing partnership with Labcorp. On the negative side, a prominent financial forecast predicted further decline in ILMN's stock price, citing short-term bearish waves and technical indicators. Additionally, several high-scoring negative scientific articles, though not directly detailing company-specific operational issues, contributed substantially to the overall negative sentiment volume.


Sentiment Breakdown

Category	Count	Percentage
Positive	20	22.0%
Negative	27	29.7%
Neutral	44	48.4%
Total	91	100.0%

Overall Sentiment: MIXED

Sentiment Trend Over Time

illumina (ILMN) - Sentiment Trend (30 Days)



Key Findings

Finding
✓ Illumina Inc. stock outperforms competitors on strong trading day
✓ Is Illumina (ILMN) a Great Long-Term Investment?
✓ Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. \$ILMN
✗ Recalibrating the epigenetic clock reveals divergent DNA methylation age signatures across schizophrenia, bipolar disorder and major depressive disorder.
✗ hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types.
✗ Illumina price gives in to negative pressure - Forecast today - 24-03-2026

Top Positive Events

Title	Source	Date	Score
Illumina Inc. stock outperforms competitors on str...	alpha_vantage	2026-03-19	0.711
Is Illumina (ILMN) a Great Long-Term Investment?	reddit	2026-03-22	0.625

Quinn Opportunity Partners LLC Sells 62,423 Shares...	alpha_vantage	2026-03-15	0.612
Illumina and Labcorp Expand Precision Oncology Tes...	alpha_vantage	2026-03-20	0.518
US Multiomic Market Set to Boom Rapidly, Witnessin...	alpha_vantage	2026-03-24	0.511

Top Negative Events

Title	Source	Date	Score
Recalibrating the epigenetic clock reveals diverge...	pubmed	2026 Mar 2	-0.821
hsa-miR-1246 is Consistently Overexpressed in Sphe...	pubmed	2026-03-29	-0.791
Illumina price gives in to negative pressure - For...	alpha_vantage	2026-03-24	-0.710
Bayesian Elastic Net Cox Models for Time-to-Event ...	pubmed	2026 Feb 2	-0.660
Immunological effects of amivantamab in EGFR or ME...	pubmed	2026 Mar 2	-0.660